Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Alan P. Skarbnik, Franklin L. Chen, Luke Mountjoy, Zaw Win Myint, Patricia A. Young, Andrew R. Whiteley, Steven Novick, Jennifer Su, Qingxi Wang, Kevin Romanko, Xi-De Wang, Yejia Li, Shulin Zhong, Liping Song, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 12059–12060.

https://doi.org/10.1182/blood-2022-164746

Published: 2022

Journal Articles

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Michel Delforge, MDPhD, Rachid C. Baz, MD, Michele Cavo, Natalie S. Callander, MD, Armin Ghobadi, MD, Paula Rodriguez-Otero, MD PhD, María-Victoria Mateos, MD PhD, Monica Massaro, MPH, Li Ding, Payal Patel, Gianfranco Pittari, MD PhD, Steven Novick, MDPhD, Sergio A. Giralt, MD, Jesus G. Berdeja, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137156

Published: 2020

Journal Articles

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, MDMBBS,MBA, Jesus G. Berdeja, MD, Anna Truppel-Hartmann, MD, Marie-Laure Casadebaig, Honeylet Wortman-Vayn, Suresh G. Shelat, PhD, Steven Novick, MDPhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139009

Published: 2020

Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Blood (2011) 118 (21): 3770.

https://doi.org/10.1182/blood.V118.21.3770.3770

Published: 2011

Journal Articles

5-Year Follow-up of Patients with Relapsed/Refractory CLL Treated with Standard Chemotherapy with or without Oblimersen in Randomized Phase III Trial: Prognostic Factors and Predictive Factors for Treatment Effect

Susan O’Brien, M.D., Jane Wu, PhD, Steven Novick, MD, PhD, Kanti R. Rai, MD

Blood (2008) 112 (11): 4201.

https://doi.org/10.1182/blood.V112.11.4201.4201

Published: 2008

Journal Articles

Addition of Oblimersen (Bcl-2 Antisense) to Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic Lymphocytic Leukemia Extends Survival in Patients Who Achieve CR/nPR: Results from a Randomized Phase 3 Study.

Susan O’Brien, Joseph Moore, Lily Ding, Steven Novick, Kanti Rai

Blood (2007) 110 (11): 751.

https://doi.org/10.1182/blood.V110.11.751.751

Published: 2007

Journal Articles

Phase 1 Assessment of an Orally Bioavailable Formulation of Gallium Nitrate (G4544).

Thomas Julian, Shingai Majuru, Moses Oyewumi, Steven Novick, Miriam Mangelus, Bob Brown, Bharat Mehta, Raymond P. Warrell, Jr., Lewis H. Bender

Blood (2007) 110 (11): 4455.

https://doi.org/10.1182/blood.V110.11.4455.4455

Published: 2007

Journal Articles

Phase 2 Multicenter Trial of Gallium Nitrate in Patients with Advanced Non-Hodgkin’s Lymphoma (NHL).

Barbara Pro, MD, R. G. Bociek, MD, Christopher R. Chitambar, MD, Stephanie A. Gregory, MD, John P. Leonard, MD, Sandra Smith, Steven Novick, MD

Blood (2004) 104 (11): 2487.

https://doi.org/10.1182/blood.V104.11.2487.2487

Published: 2004

Journal Articles

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Asher Alban Chanan-Khan, MD, Blanche Mavromatis, MD, Kanti R. Rai, MD, Philomena Casey, Steven Novick, MD, Loretta M. Itri, MD

Blood (2004) 104 (11): 4827.

https://doi.org/10.1182/blood.V104.11.4827.4827

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

5-Year Follow-up of Patients with Relapsed/Refractory CLL Treated with Standard Chemotherapy with or without Oblimersen in Randomized Phase III Trial: Prognostic Factors and Predictive Factors for Treatment Effect

Addition of Oblimersen (Bcl-2 Antisense) to Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic Lymphocytic Leukemia Extends Survival in Patients Who Achieve CR/nPR: Results from a Randomized Phase 3 Study.

Phase 1 Assessment of an Orally Bioavailable Formulation of Gallium Nitrate (G4544).

Phase 2 Multicenter Trial of Gallium Nitrate in Patients with Advanced Non-Hodgkin’s Lymphoma (NHL).

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology